The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients
Background: Anti-programmed cell death 1 (PD-1) monoclonal antibodies (Abs) unleash an immune response to cancer. However, a disruption of the immune checkpoint function by blocking PD-1/PD-ligand 1(PD-L1) signaling may trigger myasthenia gravis (MG) as a life-threatening immune-related adverse even...
Main Authors: | Koichi Saruwatari, Ryo Sato, Shunya Nakane, Shinya Sakata, Koutaro Takamatsu, Takayuki Jodai, Remi Mito, Yuko Horio, Sho Saeki, Yusuke Tomita, Takuro Sakagami |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/2/140 |
Similar Items
-
Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma
by: Ryuichi Saito, et al.
Published: (2021-02-01) -
Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China
by: Takaaki Mizuno, et al.
Published: (2022-08-01) -
Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
by: Hikaru Nanamori, et al.
Published: (2022-01-01) -
A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors
by: Maria V. Deligiorgi, et al.
Published: (2023-04-01) -
The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
by: Maria V. Deligiorgi, et al.
Published: (2021-10-01)